Clearmind Medicine has filed a patent for a new combination therapy for addiction, involving Ibogaine and Palmitoylethanolamide (PEA). The therapy, developed in collaboration with SciSparc, aims to improve the safety and efficacy of Ibogaine-based treatments for opioid, cocaine, and other substance use disorders.
Psyence Biomedical, a biotechnology company focused on natural psychedelic-based solutions for mental health, has announced significant progress in its clinical trials and partnerships. The company is currently conducting a Phase IIb clinical trial in Australia for psilocybin-assisted therapy for Adjustment Disorder in palliative care and is expanding its pipeline into Substance Use Disorders, particularly Alcohol Use Disorder (AUD). These developments position Psyence for key data readouts in 2025, potentially leading to commercial success.
The FDA has requested additional phase 3 trials for MDMA-assisted psychotherapy for PTSD, putting a hold on potential landmark approval. Despite this setback, Lykos Therapeutics remains committed to navigating the FDA’s requirements, while other psychedelic therapies continue to progress in clinical trials.
Psyence Biomedical has initiated the first clinical trial site in Australia for its Phase IIb study exploring the potential of psilocybin as a treatment for Adjustment Disorder in palliative care patients. The trial, conducted in partnership with Fluence and iNGENū CRO, aims to assess the efficacy of Psyence’s naturally sourced psilocybin drug, PEX010, and could pave the way for a pivotal Phase III program.
A new study reveals that while LSD dosage is a primary driver of its effects, individual differences in mood, personality, and prior psychedelic experience significantly influence the experience. The study underscores the importance of tailoring psychedelic therapies to individual needs.
A new study reveals growing interest among athletes and sports staff in the U.S. and Canada towards using psychedelic-assisted therapy (PAT) for concussion recovery. The research, published in Therapeutic Advances in Psychopharmacology, surveyed 175 individuals, finding a significant willingness to explore PAT, particularly with psilocybin, as a treatment option for sports-related head injuries. This study highlights the potential of psychedelics in sports medicine and opens doors for further research into their efficacy and safety.
Drug Science and University College London (UCL) have announced a strategic partnership to further investigate the efficacy of MDMA-assisted psychotherapy. This collaboration aims to address concerns raised by the FDA regarding the therapy’s regulation and therapist training, focusing on understanding the intricate interplay between MDMA and various psychotherapeutic approaches. The research will involve studying how different therapeutic modalities impact the effectiveness of MDMA treatment, ultimately aiming to provide a clearer understanding of the therapy’s potential for treating mental health conditions.
AJNA BioSciences is a company focused on developing a new class of drugs derived from botanicals, aiming to address the increasing consumer demand for natural health solutions. They are currently developing two drug candidates, CBD for Autism Spectrum Disorder and Psilocybin for Generalized Anxiety Disorder, with a commitment to ethical and sustainable research practices. AJNA’s approach leverages the growing acceptance of psychedelic-assisted therapy and the FDA’s evolving regulations for botanical drugs, potentially paving the way for a new era of natural medicine.
Emory University researchers have been awarded a $200,000 grant by the Multidisciplinary Association for Psychedelic Studies (MAPS) to conduct a pilot study exploring the potential of MDMA-assisted therapy in combination with Massed Exposure Therapy (MPE) for treating Post-Traumatic Stress Disorder (PTSD). This study, led by renowned PTSD treatment expert Dr. Barbara Rothbaum, aims to investigate the synergistic effects of these two therapies in helping individuals process traumatic memories and reduce distress.
Psychedelic-assisted therapy using substances like ketamine, MDMA, and psilocybin has gained attention for its potential benefits in treating mental health conditions. However, a recent study highlights the crucial role of strong relationships between patients and therapists in determining the effectiveness of psilocybin therapy for depression. The study suggests that a positive therapeutic alliance fosters long-term efficacy and positive psychological insights, emphasizing the importance of a supportive and safe environment for psychedelic experiences.
